The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivanov S.V.

Mental Health Research Center

Goryunov A.V.

Mental Health Research Center

Pharmacotherapy of schizophrenia: clinical and some age-related aspects

Authors:

Ivanov S.V., Goryunov A.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7): 41‑50

DOI: 10.17116/jnevro202412407141

Views: 533

Downloaded: 2

Buy for 200₽
Contact the author
Table of contents

To cite this article:

Ivanov SV, Goryunov AV. Pharmacotherapy of schizophrenia: clinical and some age-related aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7):41‑50. (In Russ.)
https://doi.org/10.17116/jnevro202412407141

Подписка 2025 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata

The article discusses modern approaches to the rational choice of therapy for schizophrenia in accordance with the principles of personalized medicine. Clinical markers for determining the optimal treatment tactics are considered depending on the syndromic features and stereotype of the course of the disease, and the possibility of justified combination therapy with drugs of different pharmacological classes. The specifics of the treatment of schizophrenia in childhood/adolescence and adult are discussed, including the basic principles of choosing drug classes, daily doses and drug therapy tactics.

Keywords:

schizophrenia
pharmacotherapy
antipsychotics
childhood
adult

Authors:

Ivanov S.V.

Mental Health Research Center

Goryunov A.V.

Mental Health Research Center

Received:

01.05.2024

Accepted:

08.05.2024

List of references:

  1. The Russian Society of Psychiatrists (ROP). Schizophrenia. Clinical recommendations (approved by the Ministry of Health of the Russian Federation), 2021—2023. (In Russ.). https://library.mededtech.ru/rest/documents/KP451/?ysclid=lpxv8f7son618037748#3
  2. Mosolov SN. Biologicheskie metody terapii psihicheskih rasstrojstv (dokazatel’naya medicina — klinicheskoj praktike). Pod red. S.N. Mosolova. M.: Izdatel’stvo «Social’no-politicheskaya mysl’». 2012;1080. (In Russ.).
  3. Neznanov NG, Aleksandrovskij YuA. Racional’naya farmakoterapiya v psihiatricheskoj praktike: rukovodstvo dlya praktikuyushchih vrachej. Pod obshch. red. Yu.A. Aleksandrovskogo, N.G. Neznanova. M.: Litterra. 2014;1080. (In Russ.).
  4. Shmukler A.B. Shizofreniya. M.: GEOTAR-Media. 2021;176. (In Russ.).
  5. Fusar-Poli P. The Clinical High-Risk State for Psychosis (CHR-P), Version II. Schizophr Bull. 2017;43(1):44-47.  https://doi.org/10.1093/schbul/sbw158
  6. Bora E, Binnur Akdede B, Alptekin K. Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med. 2017;47(14):2401-2413. https://doi.org/10.1017/S0033291717000952
  7. O’Keeffe D, Kinsella A, Waddington JL, et al. Clarke M. 20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis. Am J Psychiatry. 2022;179(4):288-297.  https://doi.org/10.1176/appi.ajp.2021.20111658
  8. Kaleda VG, Omelchenko MA, Rumyantsev AO. Psychotic risk in adolescence. Psychiatry and psychopharmacotherapy. 2017;19(2):27-33. (In Russ.).
  9. Fusar-Poli P, Salazar de Pablo G, Correll CU, et al. Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. JAMA Psychiatry. 2020;77(7):755-765.  https://doi.org/10.1001/jamapsychiatry.2019.4779
  10. Sommer IE, Bearden CE, van Dellen E, et al. Early interventions in risk groups for schizophrenia: what are we waiting for? NPJ Schizophr. 2016;2:16003. https://doi.org/10.1038/npjschz.2016.3
  11. Murru A, Carpiniello B. Duration of untreated illness as a key to early intervention in schizophrenia: A review. Neurosci Lett. 2018;669:59-67.  https://doi.org/10.1016/j.neulet.2016.10.003
  12. The National Institute for Health and Care Excellence. NICE guidance, Psychosis and schizophrenia in adults: prevention and management. 2014. https://www.nice.org.uk/guidance/cg178/chapter/1-Recommendations#preventing-psychosis-2.
  13. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015;30(3):388-404.  https://doi.org/10.1016/j.eurpsy.2015.01.013
  14. Smulevich AB. The new psychopathological paradigm of schizophrenia and schizophrenia spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):7-15. (In Russ.). https://doi.org/10.17116/jnevro20241240117
  15. Pandurangi AK, Buckley PF. Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia. Curr Top Behav Neurosci. 2020;44:227-244.  https://doi.org/10.1007/7854_2019_91
  16. de Bartolomeis A, Barone A, Vellucci L, et al. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review. Mol Neurobiol. 2022;59(10):6460-6501. https://doi.org/10.1007/s12035-022-02976-3
  17. van der Gaag M, Smit F, Bechdolf A, et al. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res. 2013;149(1-3):56-62.  https://doi.org/10.1016/j.schres.2013.07.004
  18. Mosolov SN, Yaltinskaya PA. Algorithm of therapy of primary negative symptoms in schizophrenia. Modern therapy of mental disorders. 2020;2:2-10. (In Russ.). https://doi.org/10.21265/PSYPH.2020.26.17.001
  19. Leucht S, Leucht C, Huhn M, et al. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017;174(10):927-942.  https://doi.org/10.1176/appi.ajp.2017.16121358
  20. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al, Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951.  https://doi.org/10.1016/S0140-6736(19)31135-3
  21. Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31(10):2318-2325. https://doi.org/10.1038/sj.npp.1301147
  22. Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216-229.  https://doi.org/10.1176/appi.ajp.2016.16050503
  23. Mosolov SN, Tsukarzi EE, Alfimov PV. Algorithms of biological therapy of schizophrenia. Modern therapy of mental disorders. 2014;1:27-36. (In Russ.).
  24. Seppälä A, Pylvänäinen J, Lehtiniemi H et al. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia — A systematic review and meta-analysis. Schizophr Res. 2021;236:123-134.  https://doi.org/10.1016/j.schres.2021.08.005
  25. Siskind D, Orr S, Sinha, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115-120.  https://doi.org/10.1192/bjp.2021.61
  26. Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981-1989. https://doi.org/10.1017/S0033291717000435
  27. Siskind D, McCartney L, Goldschlager R, KiselyS. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385-392.  https://doi.org/10.1192/bjp.bp.115.177261
  28. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213.  https://doi.org/10.1093/schbul/sbs150
  29. Emsley R, Asmal L, Rubio JM, et al. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res. 2020;225:55-62.  https://doi.org/10.1016/j.schres.2019.11.025
  30. Rubio JM, Taipale H, Correll CU, et al. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychol Med. 2020;50(8):1356-1367. https://doi.org/10.1017/S0033291719001296
  31. Land R, Siskind D, Mcardle P, et al. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017;135(4):296-309.  https://doi.org/10.1111/acps.12700
  32. Vermeulen JM, van Rooijen G, van de Kerkhof, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. 2019; 45(2):315-329.  https://doi.org/10.1093/schbul/sby052
  33. McEvoy JP, Lieberman JA, Stroup TS, et al. CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610.  https://doi.org/10.1176/appi.ajp.163.4.600
  34. Samara MT, Dold M, Gianatsi M, et al. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA Psychiatry. 2016;73(3):199-210.  https://doi.org/10.1001/jamapsychiatry.2015.2955
  35. Rancans E, Dombi ZB, Mátrai P, et al. The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study. Int Clin Psychopharmacol. 2021;36(3):154-161.  https://doi.org/10.1097/YIC.0000000000000351
  36. Mosolov SN. Primenenie transkranial’noj magnitnoj stimulyacii v psihiatrii. Ivanovo: Nejrosoft. 2023;576. (In Russ.).
  37. Bighelli I, Rodolico A, Siafis S, et al. Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. Cochrane Database Syst Rev. 2022;8(8):CD014383. https://doi.org/10.1002/14651858.CD014383.pub2
  38. Tiihonen J, Taipale H, Mehtala, J, et al. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia. JAMA psychiatry. 2019;76:499-507.  https://doi.org/10.1001/jamapsychiatry.2018.4320
  39. Kaar SJ, Natesan S, McCutcheon R, et al. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704. https://doi.org/10.1016/j.neuropharm.2019.107704
  40. Galling B, Roldan A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16(1):77-89.  https://doi.org/10.1002/wps.20387
  41. Ivanov SV, Smulevich AB, Borisova PO, et al. Therapy of catatonia in the clinical space of schizophrenia and schizophrenic spectrum disorders. Psychiatry. 2022;20(3):112-123. (In Russ.). https://doi.org/10.30629/2618-6667-2022-20-3-112-123
  42. Rasmussen S, Mazurek M, Rosebush P. Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology. World J Psychiatry. 2016;6(4):391.  https://doi.org/10.5498/wjp.v6.i4.391
  43. Zaman H, Gibson RC, Walcott G. Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses. Cochrane Database Syst Rev. 2019;8(8):CD006570. https://doi.org/10.1002/14651858.CD006570.pub3
  44. Ungvari GS, Chiu HF, Chow LY, et al. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology (Berl). 1999;142(4):393-398.  https://doi.org/10.1007/s002130050904
  45. Avruckij GYa, Neduva AA. Lechenie psihicheski bol’nyh. M.: Medicina. 1988;496. (In Russ.).
  46. Tiganov AS. Febril’naya shizofreniya. M: Medicina. 1982;128. (In Russ.).
  47. Cygankov BD, Ovsyannikov SA. Psihiatriya. M.: GEOTAR-Media. 2012;384. (In Russ.).
  48. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992;31(6):1161-1164. https://doi.org/10.1097/00004583-199211000-00028
  49. Lee JW. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol. 2010;30(1):3-10.  https://doi.org/10.1097/JCP.0b013e3181c9bfe6
  50. Muneoka K, Kanahara N, Kimura S. Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases. SAGE Open Med Case Rep. 2017;5:2050313X17692936. https://doi.org/10.1177/2050313X17692936
  51. Bush G, Fink M, Petrides G, et al. Rating scale and standardized examination. Acta Psychiat Scand. 1996;93(2):129-136.  https://doi.org/10.1111/j.1600-0447.1996.tb09814.x
  52. Suzuki K, Awata S, Matsuoka H. One-year outcome after response to ECT in middle-aged and elderly patients with intractable catatonic schizophrenia. J ECT. 2004;20(2):99-106.  https://doi.org/10.1097/00124509-200406000-00005
  53. Hatta K, Miyakawa K, Ota T, et al. Maximal Response to Electroconvulsive Therapy for the Treatment of Catatonic Symptoms. J ECT. 2007;23(4):233-235.  https://doi.org/10.1097/yct.0b013e3181587949
  54. Smulevich AB. Negativnye rasstrojstva v psihopatologicheskom prostranstve shizofrenii. 2-e izd. M.: MEDpress-inform. 2023;248. (In Russ.).
  55. Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103-1113. https://doi.org/10.1016/S0140-6736(17)30060-0
  56. Smulevich AB, Ivanov SV, Yakhin KK, et al. Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study). S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12):67-72. (In Russ.). https://doi.org/10.17116/jnevro202012012167
  57. Werner FM, Coveñas R. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. Ther Clin Risk Manag. 2015;11:1657-1661. https://doi.org/10.2147/TCRM.S64915
  58. Misiak B, Bieńkowski P, Samochowiec J. Cariprazine — a novel antipsychotic drug and its place in the treatment of schizophrenia. Psychiatr Pol. 2018;52(6):971-981.  https://doi.org/10.12740/PP/OnlineFirst/80710
  59. Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: Distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7(1):29-41. 
  60. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet. 2009;373(9657):31-41.  https://doi.org/10.1016/s0140-6736(08)61764-x
  61. Davis MC, Horan WP, Marder SR. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol. 2014;24(5):788-799.  https://doi.org/10.1016/j.euroneuro.2013.10.010
  62. Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625-639.  https://doi.org/10.1007/s00406-018-0869-3
  63. Makushkin EV, Simashkova NV, Perezhogin LO, et al. Schizophrenia in childhood and adolescence. Russian Psychiatric Journal. 2016;(6):62-81. (In Russ.).
  64. Goryunov AV. Using Lurasidone in the treatment of mental illness in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11-2):77-85. (In Russ.). https://doi.org/10.17116/jnevro202112111277
  65. Shtal S. Rukovodstvo dlya praktikuyushchih vrachej: deti i podrostki. S. Shtal; per. s angl. M.: MEDprecs-inform. 2022;742. (In Russ.).
  66. Correll CU, Findling RL, Tocco M, et al. Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. CNS Spectr. 2022;27(1):118-128.  https://doi.org/10.1017/S1092852920001893

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.